Rising Healthcare Expenditures Fueling Growth In The Biosimilars Market Is Supporting Development Across The Biosimilars Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Biosimilars Market Become By 2030 Compared To 2026?

The biosimilars market size has experienced considerable growth recently. This market is set to expand from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. Historically, this expansion has been attributed to several factors including the increasing occurrence of chronic and autoimmune diseases, the significant cost associated with originator biologics, a rising preference for more economical therapies, breakthroughs in biopharmaceutical research and development, and the development of healthcare infrastructure in emerging economies.

The biosimilars market size is projected to undergo substantial growth over the next few years, with expectations to reach **$48.52 billion by 2030**, expanding at a compound annual growth rate (CAGR) of **17.4%**. This anticipated growth throughout the forecast period is primarily driven by the expiration of patents for significant biologics, a rising adoption of biosimilars within oncology and autoimmune treatments, supportive government incentives and policies, an increase in manufacturing capacities across Asia-Pacific, and strengthening partnerships between biopharma companies and contract manufacturing organizations. Noteworthy trends during this same period include the advancement of personalized biosimilar development, the focus on cost-effective biologics manufacturing, efforts towards regulatory harmonization and compliance, the expansion of new markets for biosimilars, and various strategic collaborations and partnerships.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Which Significant Factors Are Encouraging Growth In The Biosimilars Market?

Rising healthcare spending is anticipated to boost the expansion of the biosimilars market in the future. Healthcare expenditures signify the cumulative outlay for medical goods and services within a specific population or system. The biosimilars market contributes to decreasing healthcare costs by providing more economical substitutes for costly biologic medications, thus reducing treatment expenses for both patients and healthcare providers. For example, in March 2024, the Health Foundation, a UK-based independent charity and think tank, reported that England’s total health expenditures hit £182 billion ($196.78 billion) in the most recently confirmed spending year, 2022/23. Although projected health spending is slated to increase to £192 billion ($207.59 billion) by 2024/25, inflationary pressures mean that the actual real-term growth will be a mere 0.6% when compared to the 2023/24 fiscal year. Consequently, the upward trend in healthcare expenditures is propelling the expansion of the biosimilars market.

What Key Segment Areas Are Included In The Biosimilars Market Assessment?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

Which Trends Are Guiding The Development Of The Biosimilars Market?

Leading companies within the biosimilars market are concentrating on developing innovative products to achieve a competitive edge. FYLNETRA functions as a leukocyte growth factor, prescribed to lessen the occurrence of infection, as shown by febrile neutropenia, in individuals with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs linked to a clinically significant incidence of febrile neutropenia. As an illustration, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, initiated the commercial release of FYLNETRA (pegfilgrastim-pbbk), a biosimilar that references Neulasta, presented in a pre-filled single-dose syringe. FYLNETRA is utilized for the treatment of neutropenia, a condition characterized by low neutrophils (a form of white blood cell crucial for fighting infection), which is commonly experienced by patients undergoing chemotherapy.

Who Are The Key Market Participants In The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Holds The Largest Share In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795